NDAORALCAPSULE
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
COXANTO (oxaprozin) by Teva is cyclooxygenase inhibitors [moa]. First approved in 2023.
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COXANTO (oxaprozin) is an oral nonsteroidal anti-inflammatory drug (NSAID) approved in October 2023 that works by inhibiting cyclooxygenase enzymes to reduce inflammation and pain. It is a small-molecule capsule formulation indicated for inflammatory conditions managed with COX inhibitors. The drug targets patients requiring long-term anti-inflammatory therapy with an oral delivery preference.
Growth
Early-stage growth product with moderate competitive pressure (30% intensity) suggests expanding commercial infrastructure needs for field teams and brand management.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Drug-drug Interaction Study of FYU-981 and Oxaprozin
Started Nov 2017
12 enrolled
Healthy
Career Relevance
COXANTO currently shows zero linked job postings, indicating early-stage commercial buildout with limited hiring visibility at present. Career roles will likely emerge in brand management, field sales, and medical affairs as market penetration accelerates and competitive pressure increases.
Brand Manager
Worked on COXANTO at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.